Top Markets
#1 Black Phoenix Black Phoenix +732.64%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.80%
#3 TENDIES TENDIES +22.99%
#4 THORChain THORChain +18.96%
#5 Biconomy Biconomy +18.30%
#6 MetaDAO MetaDAO +16.83%
#7 Wrapped STX (Velar) Wrapped STX (Velar) +16.29%
#8 Pons Pons +16.01%
#9 Moolah Moolah +15.93%
#10 THORChain Yield THORChain Yield +13.92%
Coin of the day
Black Phoenix Black Phoenix
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Mirati Therapeutics, Inc. Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc.

MRTX
Classement en actions #5110
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
Prix de l'action
$58.70
Dernière synchronisation: 2024-01-23
Capitalisation boursière
$2.98B
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Mirati Therapeutics, Inc. (MRTX)

Catégorie

Healthcare
Bénéfices pour Mirati Therapeutics, Inc. (MRTX)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Mirati Therapeutics, Inc., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Mirati Therapeutics, Inc. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH